Ablynx - Publication in accordance with §14 of the Belgian law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy" law) (1)


Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Bank of America Corporation on 2 November 2017.

Bank of America Corporation (taking into account the holdings of its subsidiary undertakings) notified Ablynx that they hold 3,151,686 voting securities of Ablynx and equivalent financial instruments on 27 October 2017, representing 4.32% of the 73,006,144 outstanding voting rights of Ablynx at that time, and thereby passively downward crossing the threshold of 5%.


The notification contains the following information:

  • Reason for the notification: passive crossing of a threshold
  • Notification by: a parent undertaking or a controlling person
  • Persons subject to the notification requirement: Bank of America Corporation, Wilmington, DE, USA
  • Date on which threshold is crossed: 27 October 2017
  • Threshold that is crossed: 5%
  • Denominator: 73,006,144 (on 27 October 2017)
  • Details of the notification:

Name of select subsidiaries of

Bank of America Corporation

% of voting rights

% of voting rights held through financial instruments*

Total of both

Merrill Lynch Pierce, Fenner & Smith Incorp.




Bank of America, National Association




Merrill Lynch Professional Clearing Corp.








* Type of financial instrument: "Right of Use"


  • Chain of controlled undertakings through which the holding is effectively being held: Bank of America, National Association, Merrill Lynch Professional Clearing Corporation and Merrill Lynch Pierce, Fenner & Smith Incorporated are controlled by Bank of America Corporation. Bank of America Corporation is not a controlled entity.
  • Additional information: The right of use represent a right of rehypothecation (not yet exercised) that Merrill Lynch Professional Clearing Corporation has over stock held on behalf of Prime Brokerage clients.


More information is provided in the transparency notification. Full versions of the transparency notifications are available on Ablynx website, under the section Investors.


The Articles of the Association of Ablynx NV provide for shareholders notification threshold of 3%, 5% or a multiple of 5% of the total number of existing voting rights.


Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.



Interested in a regular update of the Life Sciences and biotech sector in Flanders?